The Strategic Blueprint: JDRF’s Research Priorities

Type 1 diabetes (T1D) is an autoimmune condition that destroys the insulin-producing beta cells of the pancreas. For decades, management relied on manual blood glucose checks and insulin injections. Today, organizations like JDRF (formerly the Juvenile Diabetes Research Foundation) are reshaping the landscape through targeted, high-impact research investments. Their strategic portfolio focuses on three pillars: replacing or regenerating beta cells, modulating the immune system to halt the autoimmune attack, and perfecting closed-loop technology that automatically manages blood glucose. By funding both foundational science and late-stage clinical trials, JDRF aims to accelerate the transition from laboratory breakthroughs to bedside therapies.

JDRF’s investment model prioritizes translational research—moving concepts from preclinical validation into human studies. In 2023 alone, the organization committed over $110 million to T1D research across 20 countries. This capital supports collaborations between academic institutions, biotech start-ups, and pharmaceutical giants, ensuring that promising ideas receive the resources needed to reach patients.

Pillar 1: Restoring Natural Insulin Production

Beta Cell Replacement and Regeneration

The ultimate cure for T1D requires restoring the body’s ability to produce insulin on demand. Beta cell replacement strategies include transplanting donor islets (already performed in select centers) and generating new beta cells from stem cells. JDRF has been a leading funder of the ViaCyte (now Vertex) stem cell-derived islet replacement program, which recently showed early clinical proof-of-concept. In a landmark trial, patients received encapsulated stem cell-derived beta cells that began to secrete insulin in response to glucose—some reduced their insulin needs by more than 50%.

Researchers are also exploring beta cell regeneration using small molecules that coax remaining beta cells to proliferate or induce alpha cells or ductal cells to transdifferentiate into insulin producers. JDRF-funded work at the University of California, San Diego, identified a combination of drugs that can trigger beta cell replication in adult human cells. While still in early stages, this approach could one day eliminate the need for transplants.

Encapsulation: Protecting Transplanted Cells

If new beta cells are created, they must be shielded from the immune system. JDRF invests heavily in immunoprotective encapsulation devices—pouches or coatings that allow insulin to exit and glucose to enter but block immune cells. The company Sernova, supported by JDRF, is testing a subcutaneous “cell pouch” that houses donor islets. Early data show the device can maintain insulin production for over a year without immunosuppression. A larger Phase 2 trial is expected to begin in 2025.

Pillar 2: Halting the Autoimmune Attack

Immune Modulation and Prevention

T1D is driven by autoreactive T cells that destroy beta cells. JDRF has been a key backer of Teplizumab, the first drug approved by the FDA to delay the onset of T1D in at-risk individuals. Teplizumab is a humanized monoclonal antibody that dampens the autoimmune response, preserving beta cell function for months to years. The landmark TrialNet study, co-funded by JDRF and the NIH, showed that a single 14-day course of Teplizumab delayed disease progression by a median of two years in high-risk relatives. This breakthrough has opened the door to screen-and-intervene programs now being rolled out in several countries.

Other immune modulation strategies under JDRF-funded investigation include:

  • Antigen-specific therapies that train the immune system to tolerate beta cell proteins, such as oral insulin or GAD-alum vaccines.
  • Regulatory T cell (Treg) therapy where patients receive infusions of expanded Tregs to suppress the autoimmune response.
  • Low-dose anti-thymocyte globulin combined with granulocyte colony-stimulating factor to rebalance the immune system.

These approaches aim to arrest the disease early—ideally before significant beta cell loss occurs. JDRF’s TrialNet network continues to screen relatives of people with T1D, enabling early intervention trials that could prevent the disease entirely.

Pillar 3: Perfecting Automated Glucose Control

Continuous Glucose Monitoring (CGM)

While research toward a cure progresses, improved management technologies are transforming daily life. JDRF was instrumental in the development and adoption of CGM. Early funding supported the first real-time CGM systems (e.g., Dexcom G4 Platinum) and advocacy to secure insurance coverage. Today, CGM devices are smaller than a quarter and measure glucose every five minutes, providing trend arrows and alerts. JDRF-funded research has shown that CGM use reduces hemoglobin A1c by an average of 0.5 percentage points and lowers the incidence of severe hypoglycemia by 30%.

Future CGM innovations aim for fully disposable, factory-calibrated sensors that last up to 14 days, merging with smart insulin pens and artificial pancreas systems. JDRF is also funding advanced algorithms that predict glucose excursions 30–60 minutes in advance, allowing preemptive insulin adjustments.

Closed-Loop and Hybrid Closed-Loop Systems

The artificial pancreas—now called a hybrid closed-loop (HCL) system—automates insulin delivery based on CGM data. JDRF’s funding facilitated the first large-scale outpatient trials of such systems. The MiniMed 670G, launched in 2017, was the first FDA-approved HCL, and newer versions (780G, Tandem Control-IQ) now automate up to 95% of insulin adjustments. JDRF continues to support next-generation systems that also incorporate glucagon or pramlintide to mimic a normal pancreas’s dual-hormone response. A 2023 JDRF-funded study in Nature Medicine demonstrated that a dual-hormone closed-loop system maintaining glucose in range 85% of the time—a new benchmark for metabolic control.

JDRF’s Open Protocol Automated Insulin Delivery initiative aims to make these systems interoperable, allowing patients to mix and match components (sensor, pump, algorithm) rather than being locked into a single manufacturer’s ecosystem. This push for modularity could drive down costs and accelerate innovation.

Expanding Access and Overcoming Barriers

Technological breakthroughs mean little if patients cannot afford or access them. JDRF’s strategic research investments also support health economics studies and implementation science to understand barriers to adoption. For example, JDRF-funded research at the University of Michigan identified that high deductibles and lack of payer coverage delay CGM adoption for 40% of newly diagnosed T1D patients. In response, JDRF has worked with insurers to expand coverage and has advocated for state-level mandates requiring insurance plans to cover CGM for all people with T1D.

Another critical area is the integration of digital health tools. JDRF partners with companies like Tidepool to support open-source data platforms that allow patients to share their glucose data with clinicians seamlessly. The nonprofit Tidepool Loop, a mobile app that turns an iPhone into a closed-loop controller, is a direct outcome of JDRF’s early investment in open-source diabetes technology.

The Road to a Cure: Gene Therapy and Combination Approaches

No single treatment is likely to cure T1D. JDRF’s portfolio increasingly funds combination therapies that tackle both the immune attack and beta cell loss simultaneously. For instance, a Phase 2 trial testing Teplizumab combined with Verapamil (a drug that increases beta cell survival) showed preserved C-peptide levels for 12 months post-diagnosis. JDRF is also exploring gene editing as a potential one-time cure—using CRISPR to modify a patient’s own cells to evade the immune system or to correct genetic risk factors. In 2023, JDRF awarded a $5 million grant to scientists at the University of Pennsylvania to develop a CRISPR-based therapy that converts a patient’s alpha cells into glucose-responsive insulin producers without the need for immunosuppression.

Looking Ahead: The Next Decade of Diabetes Care

Thanks to JDRF’s strategic research investments, the trajectory of diabetes care is shifting from expert-driven management to automated, near-physiological regulation. Within the next decade, we can expect:

  • Preventative screenings for autoantibodies in all children, enabling early treatment with immune-modulating drugs to delay or prevent T1D entirely.
  • Closed-loop systems that integrate multiple hormones and artificial intelligence to maintain glucose levels in the non-diabetic range 90% of the time or better.
  • Bioartificial pancreas devices—implants containing stem cell-derived beta cells—that require only periodic refills
  • Gene therapies that provide a permanent cure, though still years from clinical use.

The path from laboratory to patient is long and expensive. JDRF’s role is to de-risk early-stage discoveries, gather the data needed to attract commercial partners, and advocate for regulatory and reimbursement frameworks. As the organization’s CEO recently stated, “Our goal is not just to innovate but to ensure that every innovation reaches the people who need it.”

For those living with T1D today, the rapid pace of progress offers tangible hope. The innovations JDRF funds are already reducing the burden of daily management and moving us closer to a world where diabetes no longer defines someone’s life. Continued public and private support is essential to maintain this momentum. To learn more or contribute, visit JDRF’s official website or review the latest NIDDK diabetes research overview.